[e-mail]

Oral-lyn vs. Afresa: How Generex Will Beat Mannkind

Let me give you a hint, both oralyn and alfresa are duds and will only bring pain to their investors.

Mannkind: Overlooked Biotech With Excellent Prospects (Part V)

Your diligence and effort are extraordinary. But the fact remains this is inhaling a growth factor and experts are going to worry, no matter what the data shows. If its 2 years of clean data, they'll say fine, but how do you know what will happen 5, 10, 20 years out for a therapy taken for life? How do they go about changing perceptions? Am I missing the forest for the trees or are you?

Mannkind: Overlooked Biotech With Excellent Prospects (Part I)

Very extensive work, however I think you're missing the key fact, after all that went wrong with exubera, including recently, concerns over lung cancer, what doctor in their right mind is going to advise a patient to move to inhaled insulin? With doctors more and more concerned with liability, what compelling reason would they have to switch patients from a pretty convenient and simple injection to inhaled? Why will insurance pay a premium for it? Admittedly Mannkind probably has a better mousestrap than the other inhaled's but unfortunately I think this concept is d.o.a.